How peptides came to be regulated: DQSA, FDCA, and compounding
A 2012 meningitis outbreak from one pharmacy rewrote the rules for every compounded peptide sold today.
TL;DR
- The FDCA (the 1938 Food, Drug, and Cosmetic Act) still governs every compounded peptide sold today.
- A 2012 meningitis outbreak led Congress to pass the DQSA in 2013, creating the 503A/503B compounding system.
- Peptides now sit on FDA lists called Category 1 and Category 2, which decide what pharmacies can legally compound.
What peptide regulation history covers
Peptide regulation history explains how a 1938 law still decides which peptides a pharmacy can legally compound today. The FDCA (Federal Food, Drug, and Cosmetic Act) never mentions peptides by name. It built a general approval system for new drugs. Compounding (in plain English: a pharmacist mixing a custom medicine for one patient) became a narrow exception to that system. Congress wrote the first specific compounding rules in 1997 through the FDAMA (Food and Drug Administration Modernization Act).
How the FDCA, FDAMA, and DQSA fit together
Picture compounding oversight as two lanes on one highway. 503A (the traditional lane) covers pharmacies that prepare medicine for a specific patient under a prescription, overseen by state pharmacy boards. 503B (the industrial lane) covers larger "outsourcing facilities" that compound in bulk without a prescription, overseen directly by the FDA. 2013 — the DQSA (the Drug Quality and Security Act, FDA, 2013) added Section 503B to the FDCA. A peptide can only be compounded if it appears on the matching FDA bulk-substance list.
Who asks about peptide regulation history
People come to this topic after hearing a peptide "got banned," or that another one is "back on the market." They want to know who makes these calls, and why a peptide can be legal one year and restricted the next.
What the legislative and enforcement record shows
2012 — contaminated steroid injections from the New England Compounding Center (NECC), one pharmacy, caused a fungal meningitis outbreak. More than 750 people got sick and dozens died across 20 states (FDA, 2012). Congress responded within a year, passing the DQSA (Congress.gov, 2013). Later, the FDA sorted bulk substances, including several peptides, into Category 1 (compounding permitted) and Category 2 (safety concerns identified) (FDA, Bulk Drug Substances, 2024).
What to know about why compounded peptides are regulated
The FDA regulates compounded peptides like any other compounded drug: these products skip the clinical trials required for full approval, so quality depends on the pharmacy. Compounded peptides are not FDA-approved, even when made from FDA-approved active ingredients. A prescription requires evaluation by a licensed clinician. Category 2 status reflects a current safety assessment, not a permanent ruling.
The Halftime POV
We think this backstory matters because it explains the rules, not just the rules themselves. Every peptide restriction traces back to a specific law, outbreak, or FDA review, not an arbitrary crackdown. That history helps members read regulatory news accurately instead of reacting to headlines. Halftime Health only works with peptides that are legally compoundable today, tracking category status closely.
Related reading:
- The peptide regulatory landscape in 2026
- Why the 2023 peptide compounding "ban" happened: the FDA's rationale
- 503A: what it is
- FDA reclassification, April 2026, explained
FAQ
Q: How did peptides become regulated? A: Peptides became regulated through general drug-compounding law, not a peptide-specific statute. The FDCA set the baseline in 1938, the FDAMA added the first compounding provisions in 1997, and the DQSA rebuilt that framework in 2013 after the NECC meningitis outbreak.
Q: What is the difference between 503A and 503B? A: 503A covers traditional compounding pharmacies that prepare a specific medicine for a specific patient with a prescription, overseen mainly by state pharmacy boards. 503B covers larger outsourcing facilities that compound in bulk without a patient-specific prescription and are inspected directly by the FDA.
Q: Why did the FDA start regulating compounded peptides? A: The FDA regulates compounded peptides for the same reason it regulates any compounded drug: these products are exempt from standard clinical-trial review, so oversight depends on pharmacy-level rules created after the 2012 NECC meningitis outbreak and the 2013 DQSA.
Q: What is Category 1 and Category 2 for peptides? A: Category 1 and Category 2 are FDA safety classifications for bulk substances used in compounding. Category 1 substances are generally permitted for 503A compounding, while Category 2 substances have identified safety concerns and are not part of that permitted policy.
Q: Is compounded peptide regulation the same in every state? A: No. The FDCA and DQSA set the federal floor, but 503A pharmacies are licensed and inspected primarily at the state level, so requirements for record-keeping and pharmacy oversight can vary by state even though the federal bulk-substance categories stay the same nationwide.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA
- Multistate Outbreak of Fungal Meningitis and Other Infections — FDA, 2012
- H.R.3204 — Drug Quality and Security Act, 113th Congress — Congress.gov, 2013
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — FDA
Frequently asked questions
how did peptides become regulated
Peptides became regulated through general drug-compounding law, not a peptide-specific statute. The FDCA (Federal Food, Drug, and Cosmetic Act) set the baseline in 1938, the FDAMA (Food and Drug Administration Modernization Act) added the first compounding provisions in 1997, and the DQSA (Drug Quality and Security Act) rebuilt that framework in 2013 after the NECC meningitis outbreak.
what is the difference between 503a and 503b
503A covers traditional compounding pharmacies that prepare a specific medicine for a specific patient with a prescription, overseen mainly by state pharmacy boards. 503B covers larger outsourcing facilities that compound in bulk without a patient-specific prescription and are inspected directly by the FDA.
why did the fda start regulating compounded peptides
The FDA regulates compounded peptides for the same reason it regulates any compounded drug: these products are exempt from standard clinical-trial review, so oversight depends on pharmacy-level rules created after the 2012 NECC meningitis outbreak and the 2013 DQSA.
what is category 1 and category 2 for peptides
Category 1 and Category 2 are FDA safety classifications for bulk substances used in compounding. Category 1 substances are generally permitted for 503A compounding, while Category 2 substances have identified safety concerns and are not part of that permitted policy.
is compounded peptide regulation the same in every state
No. The FDCA and DQSA set the federal floor, but 503A pharmacies are licensed and inspected primarily at the state level, so requirements for record-keeping and pharmacy oversight can vary by state even though the federal bulk-substance categories stay the same nationwide.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.